C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV

Recruiting

Phase 3

C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV

Sponsor:

Atea Pharmaceuticals, Inc.

Code:

NCT06868264

Conditions

HEPATITIS C VIRUS CHRONIC INFECTION

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Bemnifosbuvir-Ruzasvir (BEM/RZR)

Sofosbuvir-Velpatasvir (SOF/VEL)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-09. This information was provided to ClinicalTrials.gov by Atea Pharmaceuticals, Inc. on 2025-05-15.